Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Coherus Oncology, Inc.
With
Shire
Pt. 1 is a 12-week randomized, double-blind, active-control, parallel-group, multi-center global study. The primary end point is 75% improvement from baseline according to the Psoriasis Area and Severity Index (PASI-75). Comparing CHS-0214 to Enbrel for efficacy and safety at a dosage of 50mg subcutaneous (Sc) twice weekly.
Pt. 2 is a 40-week randomized, double-blind, active-control, parallel-group, multi-center global study where CHS-0214 and Enbrel dosage is reduced to 50mg Sc weekly for maintenance.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female adults
PsO diagnosis for 6 months
Active disease: PASI greater than or equal to 12, Physician's Static Global Assessment (PSGA) score greater than or equal to 3 (based on a scale or 0-5),
Body Surface Area (BSA) involved with PsO greater than or equal to 10%
Dermatology Life Quality Index (DQLI) greater than or equal to 10
Previously received phototherapy or systemic non-biologic therapy for PsO
You may not be if
Forms of Psoriasis other than PsO
Drug induced Psoriasis
Positive QuantiFERON-tuberculosis (TB) Gold Test
Presence of significant comorbid conditions
Chemistry and hematology values outside protocol specified range